Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerResearch Summary
Analyzed using Evidence Intelligence™
Tirzepatide significantly reduces body weight in Japanese adults with T2D
Last updated September 12, 2026
Key finding
Mean percent change in body weight was statistically significantly greater for tirzepatide 10 mg: -12.4% (1.8%) compared with placebo: -3.5% (1.8%)
This study evaluated the efficacy and safety of once-weekly tirzepatide in Japanese participants with obesity and type 2 diabetes, showing significant weight loss compared to placebo.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the efficacy and safety of once-weekly tirzepatide in Japanese participants with obesity and type 2 diabetes, showing significant weight loss compared to placebo.
Clinical relevance
These findings suggest that tirzepatide could be an important therapeutic option for managing obesity and type 2 diabetes, particularly in populations that may respond differently to existing treatments. Effective weight management is crucial for improving overall health and reducing diabetes-related complications.
Keep in mind
The study was limited to a specific population (Japanese participants), which may affect generalizability. The long-term safety and efficacy of tirzepatide were not assessed beyond the study duration. The trial did not include a diverse demographic, limiting applicability to broader populations.
Published in
Journal Reference
Publication details and source links for this paper.
Toshimasa Y, Taro A, Tomotaka S, Tomonori O, Hideki K. Efficacy and safety of once-weekly tirzepatide in Japanese participants with obesity and type 2 diabetes: a subpopulation analysis of the SURMOUNT-2 trial. Diabetes, Obesity & Metabolism. 2025;27(8):4557-4566. doi:10.1111/dom.16500
Main Effects
Tirzepatide 10 mg resulted in a mean percent change in body weight of -12.4% compared to -3.5% for placebo (p=0.001).
Tirzepatide 15 mg resulted in a mean percent change in body weight of -10.2% compared to -3.5% for placebo (p=0.013).
85.7% of participants on tirzepatide 10 mg achieved ≥5% body weight reduction versus 46.2% in the placebo group.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Tirzepatide 10 mg once weekly, Tirzepatide 15 mg once weekly and Body weight, Diastolic blood pressure, Fasting Plasma Glucose (FPG), and 5 more.
This study contributes evidence to
Primary intervention
Tirzepatide 10 mg once weekly
Primary outcomes
- Body weight
- Diastolic blood pressure
- Fasting Plasma Glucose (FPG)
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
16
Evidence pairs
16
Relationships
6
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
6
Related topics
16
Evidence pairs
2149
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 16 evidence relationships
- Includes primary outcome data
- Linked to 6 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Add related evidence to your Evidence Tracker
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
Weight Loss
matched_outcome
Related evidence
Evidence topic
Blood Pressure
Save evidence
Core evidence
Study findings
The primary outcomes reported in this study.
Diastolic blood pressure
Tirzepatide 10 mg once weekly → Diastolic blood pressure
Tirzepatide 10 mg once weekly → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Tirzepatide 10 mg once weekly → Fasting Plasma Glucose (FPG)
Tirzepatide 10 mg once weekly → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerProportion of participants achieving weight loss of 5% or more at 52 weeks
Tirzepatide 10 mg once weekly → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Tirzepatide 10 mg once weekly → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSafety events
Tirzepatide 10 mg once weekly → Safety events
Tirzepatide 10 mg once weekly → Safety events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSystolic blood pressure
Tirzepatide 10 mg once weekly → Systolic blood pressure
Tirzepatide 10 mg once weekly → Systolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerWaist circumference
Tirzepatide 10 mg once weekly → Waist circumference
Tirzepatide 10 mg once weekly → Waist circumference
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerDiastolic blood pressure
Tirzepatide 15 mg once weekly → Diastolic blood pressure
Tirzepatide 15 mg once weekly → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Tirzepatide 15 mg once weekly → Fasting Plasma Glucose (FPG)
Tirzepatide 15 mg once weekly → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerProportion of participants achieving weight loss of 5% or more at 52 weeks
Tirzepatide 15 mg once weekly → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Tirzepatide 15 mg once weekly → Proportion of participants achieving weight loss of 5% or more at 52 weeks
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSafety events
Tirzepatide 15 mg once weekly → Safety events
Tirzepatide 15 mg once weekly → Safety events
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerSystolic blood pressure
Tirzepatide 15 mg once weekly → Systolic blood pressure
Tirzepatide 15 mg once weekly → Systolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerWaist circumference
Tirzepatide 15 mg once weekly → Waist circumference
Tirzepatide 15 mg once weekly → Waist circumference
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Evidence Suggest
- Tirzepatide 10 mg showed a significant weight reduction of -12.4%.
- Tirzepatide 15 mg led to a weight loss of -10.2% compared to placebo.
- A high proportion (85.7%) of participants on tirzepatide 10 mg achieved significant weight loss.
Who this applies to
- Japanese adults with obesity and type 2 diabetes.
- Individuals seeking effective weight management solutions.
Keep in Mind
- Results may not be applicable to non-Japanese populations.
- Further research is needed to confirm long-term effects.
- The study focused on specific doses; effects of other doses remain unclear.
Between the Lines
- The study was limited to a specific population (Japanese participants), which may affect generalizability.
- The long-term safety and efficacy of tirzepatide were not assessed beyond the study duration.
- The trial did not include a diverse demographic, limiting applicability to broader populations.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Tirzepatide 10 mg once weekly and Body Weight, Tirzepatide 10 mg once weekly and Blood Pressure.
Related evidence relationships
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Tirzepatide 10 mg once weekly → Body Weight
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceBehavioral & Lifestyle
Tirzepatide 10 mg once weekly → Blood Pressure
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceBehavioral & Lifestyle
Tirzepatide 10 mg once weekly → Fasting Glucose
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluded in these evidence collections
Curated evidence collections and hubs this study is part of.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
1 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
1 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Tirzepatide 10 mg once weekly Evidence Hub
All studies on Tirzepatide 10 mg once weekly
1 studies
intervention_hubContributes to Tirzepatide 10 mg once weekly evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Tirzepatide 10 mg once weekly and Body weight
Intervention: Tirzepatide 10 mg once weeklyOutcome: Body weight
1 results
All studies on Tirzepatide 10 mg once weekly and Diastolic blood pressure
Intervention: Tirzepatide 10 mg once weeklyOutcome: Diastolic blood pressure
1 results
All studies on Tirzepatide 10 mg once weekly
Intervention: Tirzepatide 10 mg once weekly
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
All studies measuring Diastolic blood pressure
Outcome: Diastolic blood pressure
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Tirzepatide 10 mg once weekly affect body weight?
Emerging Evidence
Tirzepatide 10 mg once weekly appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Tirzepatide 10 mg once weekly lower HbA1c?
Emerging Evidence
Tirzepatide 10 mg once weekly appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Tirzepatide 15 mg once weekly affect body weight?
Emerging Evidence
Tirzepatide 15 mg once weekly appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Tirzepatide 15 mg once weekly lower HbA1c?
Emerging Evidence
Tirzepatide 15 mg once weekly appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
All studies on Tirzepatide 10 mg once weekly and Body weightAll studies on Tirzepatide 10 mg once weekly and Proportion of participants achieving weight loss of 5% or more at 52 weeksAll studies on Tirzepatide 15 mg once weekly and Body weightAll studies on Tirzepatide 15 mg once weekly and Proportion of participants achieving weight loss of 5% or more at 52 weeks
Related research
Read related research summaries.
High-protein diet may reduce cardiometabolic risks in diabetes patientsInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Exercise Improves Serum Albumin Levels in Women with Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesLiraglutide and Empagliflozin Improve Heart Function in Diabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.